Osborne Clarke in Amsterdam has advised iOnctura in the closing of a EUR 15 million Series A financing.
The financing was led by INKEF Capital and co-led by VI Partners with participation by new investor Schroder Adveq. iOnctura’s founding investor, M Ventures, also participated in the fundraise. iOnctura was founded in 2017 as a spin-out from Merck, with Merck and Cancer Research UK providing a best-in-class pipeline of molecules that harness both direct and immune-mediated anti-cancer activities in solid cancers and cancer fibrosis.
iOnctura is a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis.
The Osborne Clarke in Amsterdam team was led by Partner Herke van Hulst (Picture) and consisted of Senior Associate Geoffrey Beurskens, Partners Cars-Jan van Gool (Civil Law Notary) and Job van der Pol (Tax) and Associates Arlette Vrolijk (Candidate Civil-Law Notary), Aram Hovanesjan (Tax) and Florien Sanders (Corporate M&A).
Involved fees earner: Geoffrey Beurskens – Osborne Clarke; Aram Hovanesjan – Osborne Clarke; Florien Sanders – Osborne Clarke; Job van der Pol – Osborne Clarke; Cars-Jan van Gool – Osborne Clarke; Herke van Hulst – Osborne Clarke; Arlette Vrolijk – Osborne Clarke;
Law Firms: Osborne Clarke;